{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T22:37:53Z","timestamp":1778711873614,"version":"3.51.4"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2017,9,13]],"date-time":"2017-09-13T00:00:00Z","timestamp":1505260800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0182901","type":"journal-article","created":{"date-parts":[[2017,9,13]],"date-time":"2017-09-13T17:26:32Z","timestamp":1505323592000},"page":"e0182901","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":8,"title":["Copy number variation analysis in cytochromes and glutathione S-transferases may predict efficacy of tyrosine kinase inhibitors in chronic myeloid leukemia"],"prefix":"10.1371","volume":"12","author":[{"given":"Alexander V.","family":"Lavrov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oksana A.","family":"Ustaeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elmira P.","family":"Adilgereeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1558-3048","authenticated-orcid":true,"given":"Svetlana A.","family":"Smirnikhina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekaterina Y.","family":"Chelysheva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oleg A.","family":"Shukhov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuriy V.","family":"Shatokhin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergey V.","family":"Mordanov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna G.","family":"Turkina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergey I.","family":"Kutsev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2017,9,13]]},"reference":[{"issue":"1","key":"ref1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"RL Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"Suppl 2","key":"ref2","doi-asserted-by":"crossref","first-page":"S241","DOI":"10.1007\/s00277-015-2314-2","article-title":"Epidemiology of chronic myeloid leukaemia: an update","volume":"94","author":"M H\u00f6glund","year":"2015","journal-title":"Ann Hematol"},{"issue":"6","key":"ref3","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/leu.2015.73","article-title":"The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries","volume":"29","author":"VS Hoffmann","year":"2015","journal-title":"Leukemia"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/leu.2010.238","article-title":"Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia","volume":"25","author":"D Bixby","year":"2011","journal-title":"Leukemia"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/107327480901600204","article-title":"Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia","volume":"16","author":"A Quint\u00e1s-Cardama","year":"2009","journal-title":"Cancer Control"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.ejca.2009.04.005","article-title":"Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia","volume":"45","author":"E San Jos\u00e9-Eneriz","year":"2009","journal-title":"Eur J Cancer"},{"issue":"2","key":"ref7","first-page":"741","article-title":"Instability of mRNA expression signatures of drug transporters in chronic myeloid leukemia patients resistant to imatinib","volume":"29","author":"M Gromicho","year":"2013","journal-title":"Instability of mRNA expression signatures of drug transporters in chronic myeloid leukemia patients resistant to imatinib"},{"issue":"3","key":"ref8","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s12032-014-0851-5","article-title":"Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia","volume":"31","author":"LT de Lima","year":"2014","journal-title":"Med Oncol"},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3892\/or.2016.5226","article-title":"Expression of genes encoding centrosomal proteins and the humoral response against these proteins in chronic myeloid leukemia","volume":"37","author":"J \u0160mahelov\u00e1","year":"2017","journal-title":"Oncol Rep"},{"issue":"4","key":"ref10","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00280-017-3266-0","article-title":"hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia","volume":"79","author":"I Ben Hassine","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"e470","DOI":"10.1038\/bcj.2016.79","article-title":"MATE1 regulates cellular uptake and sensitivity to imatinib in CML patients","volume":"6","author":"S Harrach","year":"2016","journal-title":"Blood Cancer J"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.leu.2404270","article-title":"Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients","volume":"20","author":"O Frank","year":"2006","journal-title":"Leukemia"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1476-4598-8-69","article-title":"MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations","volume":"8","author":"E San Jose-Eneriz","year":"2009","journal-title":"Mol Cancer"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3324\/haematol.2012.066480","article-title":"Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy","volume":"98","author":"S Angelini","year":"2013","journal-title":"Haematologica"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12863-015-0308-7","article-title":"Frequent variations in cancer-related genes may play prognostic role in treatment of patients with chronic myeloid leukemia","volume":"17","author":"AV. Lavrov","year":"2016","journal-title":"BMC Genet"},{"issue":"7","key":"ref16","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.3109\/10428194.2015.1132420","article-title":"Whole-exome sequencing reveals potential molecular predictors of relapse after discontinuation of the targeted therapy in chronic myeloid leukemia patients","volume":"57","author":"SA Smirnikhina","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"ref17","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s40487-016-0035-x","article-title":"Impact of CYP3A4*18 and CYP3A5*3 Polymorphisms on Imatinib Mesylate Response Among Chronic Myeloid Leukemia Patients in Malaysia","volume":"4","author":"N Maddin","year":"2016","journal-title":"Oncol Ther"},{"issue":"3","key":"ref18","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/annonc\/mds532","article-title":"Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients","volume":"24","author":"SJ Seong","year":"2013","journal-title":"Ann Oncol"},{"issue":"6","key":"ref19","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"M Baccarani","year":"2013","journal-title":"Blood"},{"issue":"4","key":"ref20","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1080\/08998280.2000.11927719","article-title":"Drug interactions due to cytochrome P450","volume":"13","author":"CC Ogu","year":"2000","journal-title":"Proc (Bayl Univ Med Cent)"},{"issue":"9","key":"ref21","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","article-title":"Clinical pharmacokinetics of imatinib","volume":"44","author":"B Peng","year":"2005","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"ref22","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/j.1365-2125.2008.03150.x","article-title":"Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia","volume":"65","author":"Y Wang","year":"2008","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"ref23","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1177\/0004867413520050","article-title":"The role of pharmacogenomic testing in psychiatry: Real world examples","volume":"48","author":"O Dinama","year":"2014","journal-title":"Aust N Z J Psychiatry"},{"issue":"1","key":"ref24","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"UM Zanger","year":"2013","journal-title":"Pharmacol Ther"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3109\/10428194.2010.546916","article-title":"Techniques for risk stratification of newly diagnosed patients with chronic myeloid leukemia","volume":"52","author":"B Mitchell","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1080\/10428190903003236","article-title":"Meta-analysis study of glutathione-S-transferases (GSTM1, GSTP1, and GSTT1) gene polymorphisms and risk of acute myeloid leukemia","volume":"50","author":"P Das","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1182\/blood.V100.8.2703","article-title":"Negative prognostic value of glutathione S-transferase (GSTM1 and GSTT1) deletions in adult acute myeloid leukemia","volume":"100","author":"MT Voso","year":"2002","journal-title":"Blood"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/pbc.20074","article-title":"Genetic polymorphism of CYP1A1, CYP2D6, GSTM1 and GSTT1 and susceptibility to acute lymphoblastic leukaemia in Indian children","volume":"43","author":"T Joseph","year":"2004","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"ref29","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.ejca.2005.01.014","article-title":"Glutathione s-transferase polymorphisms (GSTM1, GSTP1 and GSTT1) and the risk of acute leukaemia: a systematic review and meta-analysis","volume":"41","author":"Z Ye","year":"2005","journal-title":"Eur J Cancer"},{"issue":"11","key":"ref30","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1093\/jjco\/hyu121","article-title":"Glutathione S-transferase gene polymorphisms and susceptibility to acute myeloid leukemia: meta-analyses","volume":"44","author":"HR He","year":"2014","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"ref31","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cancergencyto.2010.08.022","article-title":"GSTT1 copy number gain is a poor predictive marker for escalated-dose imatinib treatment in chronic myeloid leukemia: genetic predictive marker found using array comparative genomic hybridization","volume":"203","author":"Y Koh","year":"2010","journal-title":"Cancer Genet Cytogenet"},{"issue":"6","key":"ref32","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/clpt.2014.176","article-title":"Dual glutathione-S-transferase-teta1 and\u2013mu1 gene deletions determine imatinib failure in chronic myeloid leukemia","volume":"96","author":"A Davies","year":"2014","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"ref33","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s12032-014-0047-z","article-title":"Effect of interaction of glutathione S-transferases (T1 and M1) on the hematologic and cytogenetic responses in chronic myeloid leukemia patients treated with imatinib","volume":"31","author":"Y Kassogue","year":"2014","journal-title":"Med Oncol"},{"issue":"s1","key":"ref34","first-page":"744","article-title":"The results of tyrosine-kinase inhibitors treatment in chronic myeloid leukemia patients according to 2013 European LeukemiaNet response criteria: Russian singlecenter study","volume":"101","author":"O. Shukhov","year":"2016","journal-title":"Haematologica"},{"issue":"s1","key":"ref35","first-page":"835","article-title":"Pharmacoeconomic modelling of target therapy chronic myelogenous leukemia: early and late switching","volume":"101","author":"V. Shuvaev","year":"2016","journal-title":"Haematologica"},{"issue":"1","key":"ref36","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/biostatistics\/kxn018","article-title":"Sample size for positive and negative predictive value in diagnostic research using case\u2013control designs","volume":"10","author":"J. Fine","year":"2009","journal-title":"Biostatistics"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0182901","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T20:32:12Z","timestamp":1659472332000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0182901"}},"subtitle":[],"editor":[{"given":"Persio","family":"Dello Sbarba","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,9,13]]},"references-count":36,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2017,9,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0182901","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,13]]}}}